Cell Therapeutics Reports Results With Chemo Drug

Cell Therapeutics provided its findings from a Phase III clinical trial comparing Opaxio with gemcitabine or vinorelbine for treating patients with previously untreated nonsmall cell lung cancer.

Results from the randomized, multicenter trial showed that overall survival was similar between the Opaxio arm and control arm. Patients treated with the drug required less supportive care — including fewer red blood cell transfusions, hematopoietic growth factors and opioid analgesics — than those patients receiving either gemcitabine or vinorelbine, according to the company.

Previously called Xyotax, Opaxio is an investigational, biologically enhanced chemotherapeutic.